» Articles » PMID: 30006563

Exploring the Clinical Features of Narcolepsy Type 1 Versus Narcolepsy Type 2 from European Narcolepsy Network Database with Machine Learning

Abstract

Narcolepsy is a rare life-long disease that exists in two forms, narcolepsy type-1 (NT1) or type-2 (NT2), but only NT1 is accepted as clearly defined entity. Both types of narcolepsies belong to the group of central hypersomnias (CH), a spectrum of poorly defined diseases with excessive daytime sleepiness as a core feature. Due to the considerable overlap of symptoms and the rarity of the diseases, it is difficult to identify distinct phenotypes of CH. Machine learning (ML) can help to identify phenotypes as it learns to recognize clinical features invisible for humans. Here we apply ML to data from the huge European Narcolepsy Network (EU-NN) that contains hundreds of mixed features of narcolepsy making it difficult to analyze with classical statistics. Stochastic gradient boosting, a supervised learning model with built-in feature selection, results in high performances in testing set. While cataplexy features are recognized as the most influential predictors, machine find additional features, e.g. mean rapid-eye-movement sleep latency of multiple sleep latency test contributes to classify NT1 and NT2 as confirmed by classical statistical analysis. Our results suggest ML can identify features of CH on machine scale from complex databases, thus providing 'ideas' and promising candidates for future diagnostic classifications.

Citing Articles

Identifying time-resolved features of nocturnal sleep characteristics of narcolepsy using machine learning.

Vilela M, Tracey B, Volfson D, Barateau L, Cai A, Buhl D J Sleep Res. 2024; 33(6):e14216.

PMID: 38665127 PMC: 11596988. DOI: 10.1111/jsr.14216.


Causal Association Between Subtypes of Excessive Daytime Sleepiness and Risk of Cardiovascular Diseases.

Goodman M, Dashti H, Lane J, Windred D, Burns A, Jones S J Am Heart Assoc. 2023; 12(24):e030568.

PMID: 38084713 PMC: 10863774. DOI: 10.1161/JAHA.122.030568.


Serum metabolomics study of narcolepsy type 1 based on ultra-performance liquid chromatography-tandem mass spectrometry.

Zhan Q, Wang L, Liu N, Yuan Y, Deng L, Ding Y Amino Acids. 2023; 55(10):1247-1259.

PMID: 37689600 PMC: 10689557. DOI: 10.1007/s00726-023-03315-z.


A series of 7 cases of patients with narcolepsy with hypocretin deficiency without the HLA DQB1*06:02 allele.

Miano S, Barateau L, De Pieri M, Riccardi S, Thevenin C, Manconi M J Clin Sleep Med. 2023; 19(12):2053-2057.

PMID: 37539640 PMC: 10692923. DOI: 10.5664/jcsm.10748.


Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis.

Zhan S, Ye H, Li N, Zhang Y, Cheng Y, Wang Y Nat Sci Sleep. 2023; 15:217-230.

PMID: 37082610 PMC: 10112483. DOI: 10.2147/NSS.S404113.


References
1.
Mignot E, Hayduk R, Black J, Grumet F, Guilleminault C . HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1998; 20(11):1012-20. View

2.
Baumann C, Mignot E, Lammers G, Overeem S, Arnulf I, Rye D . Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep. 2014; 37(6):1035-42. PMC: 4015377. DOI: 10.5665/sleep.3756. View

3.
Aldrich M, Chervin R, Malow B . Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep. 1997; 20(8):620-9. View

4.
Nishino S, Ripley B, Overeem S, Lammers G, Mignot E . Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000; 355(9197):39-40. DOI: 10.1016/S0140-6736(99)05582-8. View

5.
Trotti L, Staab B, Rye D . Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med. 2013; 9(8):789-95. PMC: 3716670. DOI: 10.5664/jcsm.2922. View